Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/184278
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Soler Botija, Carolina | - |
dc.contributor.author | Monguió Tortajada, Marta | - |
dc.contributor.author | Munizaga Larroudé, Micaela | - |
dc.contributor.author | Gálvez Montón, Carolina | - |
dc.contributor.author | Bayés Genís, Antoni | - |
dc.contributor.author | Roura, Santiago | - |
dc.date.accessioned | 2022-03-22T10:31:56Z | - |
dc.date.available | 2022-03-22T10:31:56Z | - |
dc.date.issued | 2022-03-01 | - |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.uri | https://hdl.handle.net/2445/184278 | - |
dc.description.abstract | Compelling evidence supports the therapeutic benefit of extracellular vesicles (EVs). EVs are nanostructures with a lipid bilayer membrane that are secreted by multiple cells, including mesenchymal stromal cells (MSCs), as means of cellular communication. MSC-EVs, resembling their MSC origin, carry protected immunomodulatory and pro-regenerative cargoes to targeted neighboring or distant cells and tissues. Though treatments focused on MSC-EVs have emerged as greatly versatile approaches to modulate multiple inflammatory-related conditions, crucial concerns, including the possibility of increasing therapeutic outcomes by pre-conditioning parental MSCs or engineering derived EVs and clarification of the most relevant mechanisms of action, remain. Here, we summarize the large amount of preclinical research surrounding the modulation of beneficial effects by MSC-EVs. | - |
dc.format.extent | 21 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.biopha.2022.112683 | - |
dc.relation.ispartof | Biomedicine & Pharmacotherapy, 2022, vol 147 | - |
dc.relation.uri | https://doi.org/10.1016/j.biopha.2022.112683 | - |
dc.rights | cc by (c) Soler Botija, Carolina et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Apoptosi | - |
dc.subject.classification | Bioenginyeria | - |
dc.subject.other | Apoptosis | - |
dc.subject.other | Bioengineering | - |
dc.title | Mechanisms governing the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles: A scoping review of preclinical evidence | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-03-22T08:29:56Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35144050 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0753332222000713-main.pdf | 1.53 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License